Cinar Irfan, Yayla Muhammed, Celik Muhammet, Bilen Arzu, Bayraktutan Zafer
Department of Pharmacology, Kastamonu University School of Medicine, Kastamonu, Turkey.
Department of Biochemistry, Ataturk University Faculty of Medicine, Erzurum, Turkey.
Eurasian J Med. 2020 Oct;52(3):277-282. doi: 10.5152/eurasianjmed.2020.20033.
The aim of this study was to explore the role of endothelin 1 (ET-1) in human breast cancer proliferation and migration and antagonism of endothelin receptor A (ETAR) and endothelin receptor B (ETBR) by using the non-selective dual ETA/ETB receptor antagonist bosentan and determine its anti-proliferative, anti-metastatic, and apoptotic effects demonstrated by nuclear factor kappa B (NF-kB), vascular endothelial growth factor (VEGF), Caspase 3 and Caspase 9 expression on endothelin-induced proliferation of MCF-7 cell line in vitro.
A total of 8,000 cells were seeded into e-plates 24 hours after the cells were incubated with or without 10-4 M BOS (1 hour before ET-1 treatment); 10-7, 10-8, and 10-9 M ET-1 for 1-4 days.
Whether ET-1 is present or not in the tumor area, bosentan exerts anti-proliferative effect on breast cancer. However, ET-1 and bosentan group showed important inhibitory effect on tumor migration compared to bosentan alone, which can be attributed to increased activity of ET-1 axis in the presence of ET-1. The imbalance among the NF-kB, caspases, and VEGF, which are predictive factors of carcinogenesis significantly improved after bosentan administration.
Our study definitely demonstrated ET-1 and its critical role in cancer progression with apoptotic and anti-apoptotic pathways (NF-κB) and VEGF expression, and migration analyses were also performed. The second major finding was that bosentan inhibited ET-1-mediated effects on tumor proliferation and migration.
本研究旨在探讨内皮素1(ET-1)在人乳腺癌增殖和迁移中的作用,以及使用非选择性双重ETA/ETB受体拮抗剂波生坦拮抗内皮素A受体(ETAR)和内皮素B受体(ETBR),并通过核因子κB(NF-κB)、血管内皮生长因子(VEGF)、半胱天冬酶3和半胱天冬酶9的表达来确定其对内皮素诱导的MCF-7细胞系体外增殖、抗转移和凋亡的影响。
在细胞与10-4 M BOS(ET-1处理前1小时)孵育或不孵育24小时后,将总共8000个细胞接种到e-plates中;分别用10-7、10-8和10-9 M ET-1处理1 - 4天。
无论肿瘤区域是否存在ET-1,波生坦对乳腺癌均具有抗增殖作用。然而,与单独使用波生坦相比,ET-1和波生坦组对肿瘤迁移显示出重要的抑制作用,这可归因于ET-1存在时ET-1轴活性的增加。波生坦给药后,作为致癌预测因子的NF-κB、半胱天冬酶和VEGF之间的失衡得到显著改善。
我们的研究明确证明了ET-1及其在癌症进展中的关键作用,涉及凋亡和抗凋亡途径(NF-κB)以及VEGF表达,并进行了迁移分析。第二个主要发现是波生坦抑制了ET-1介导的对肿瘤增殖和迁移的影响。